Spots Global Cancer Trial Database for Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
Official Title: Radiofrequency Ablation of Pulmonary Malignancy
Study ID: NCT00024076
Interventions
Study Description
Brief Summary: RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.
Detailed Description: OBJECTIVES: * Determine the safety and toxicity of radiofrequency ablation in patients with refractory or advanced pulmonary malignancies. * Determine the efficacy of this treatment, in terms of local control, in these patients. * Determine whether CT scan is a reasonable imaging assessment tool for treatment delivery and follow-up in these patients. OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the tumor over 2 hours. Patients are followed at 1, 3, 6, and 12 months. PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
Contact Details
Name: Robert D. Suh, MD
Affiliation: Jonsson Comprehensive Cancer Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
